Mgi Tech Co.,Ltd. (688114.SH) surged over 19% in early trading, currently up 14.27% at 61.51 yuan with a turnover of 1.014 billion yuan.

AI for Science is transitioning from concept to an industrialization inflection point. Major North American tech firms are collectively doubling down on AI-driven drug development, with accelerated model training and expanded experimental demands feeding upstream. The innovative drug chain is now facing dual opportunities of value reassessment and incremental growth.

As a full-stack life science tools provider, Mgi Tech Co.,Ltd. holds a global leading position in full-read-length sequencer business, offering essential sequencing instruments for AI drug discovery. The company previously partnered with Zhuiguang Biotechnology and the National University of Singapore's Department of Pharmacy and Pharmaceutical Sciences in drug research and development.

Notably, Mgi Tech Co.,Ltd.'s subsidiary, Yongsheng Intelligence, recently jointly released two achievements with the Shanghai Artificial Intelligence Laboratory: ProtoPilot, a self-evolving multi-agent system driven by real laboratory scenarios, and BioLab Bench, the first full-process Agent evaluation system in life sciences from user requirements to executable equipment, delivering the inaugural Physical AI answer for global life science laboratories.